AbbVie's $10.9 Billion Apogee Bet: Pharma's Biggest M&A Surge in Years

A $10.9 billion immunology bet

AbbVie agreed on June 22, 2026 to acquire clinical-stage biotech Apogee Therapeutics in an all-cash deal valued at $10.9 billion, paying $135.11 per share — a 49% premium to Apogee's closing price the prior Thursday.cnbc +1 The transaction is AbbVie's largest buyout in more than five years, eclipsing its $10.1 billion purchase of cancer-drug specialist ImmunoGen in 2024.medcitynews Apogee shares surged 47% in premarket trading on the news, while AbbVie gained about 1.5%.cnbc

At the center of the deal is zumilokibart, Apogee's lead drug candidate, an antibody designed to block IL-13, a protein involved in inflammatory signaling.medcitynews On track to enter Phase 3 testing in atopic dermatitis, the drug can be injected subcutaneously once every three to six months — a meaningful improvement over existing biologics that typically require dosing every two to four weeks.cnbc +1 AbbVie Chairman and CEO Robert Michael said the acquisition "adds highly differentiated clinical-stage assets, further expanding our robust immunology portfolio in areas of significant patient need."medcitynews

Filling the gap left by Humira

The strategic logic is rooted in necessity as much as ambition. AbbVie's immunology franchise generated more than $30 billion in revenue in 2025, up 14% year-over-year, driven by blockbusters Skyrizi and Rinvoq — but Humira sales fell 49% as biosimilar competition intensified.cnbc The company has systematically reloaded its pipeline through acquisitions to offset that pressure and prepare for eventual patent cliffs on its newer drugs.cnbc

Zumilokibart also addresses a notable gap AbbVie has in atopic dermatitis. Rinvoq treats the condition but carries black-box label warnings over elevated cancer and cardiovascular risks tied to the entire JAK inhibitor drug class.medcitynews An approved IL-13 antibody with a best-in-class dosing schedule would offer physicians a compelling alternative in a market currently dominated by Sanofi and Regeneron's Dupixent, which is administered every two weeks for the same indication.cnbc +1

The broader pharma M&A surge

The deal arrives amid a record dealmaking wave. In the first half of 2026, pharmaceutical and biotech companies completed 33 acquisitions valued at $1 billion or more, spending roughly $134 billion — already surpassing all of 2025's $112 billion total.statnews Analysts point to looming patent expiration calendars as the primary fuel, with drugmakers racing to replace revenue from aging franchises before cliffs arrive.

William Blair analyst Matt Phipps described the Apogee price tag as "fairly expensive," but acknowledged that zumilokibart fits AbbVie's immunology and inflammation expertise while opening a path into respiratory indications.medcitynews RBC Capital Markets analyst Brian Abrahams added that Apogee had long been viewed as a potential takeover target because of the drug's less-frequent dosing profile and the "large and growing" atopic dermatitis market.cnbc The transaction is expected to close in the third quarter of 2026, pending regulatory and shareholder approvals, and is projected to be accretive to AbbVie's adjusted earnings per share starting in 2032.cnbc